Real-World Study Evaluating Drug Tolerability and Health Care Resource Use (HCRU) With Acalabrutinib vs Ibrutinib in Patients With Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)